RightFit
RecruitingPhase 2

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how well stereotactic radiosurgery (SRS), a focused radiation treatment, works for small cell lung cancer that has spread to the brain. It is for adults with a new diagnosis of cancer spread to the brain.

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Age 18 or older.
  • Small cell lung cancer confirmed by a tissue test.
  • An MRI scan with contrast dye shows up to 20 spots of cancer in the brain.
  • Able to do at least some daily activities, with a health activity score of KPS 60–100 or ECOG 0–2.
  • Women must be unable to become pregnant or have a negative blood pregnancy test when joining.
  • You or your legal representative can give informed consent, meaning you understand and agree to the study.

Who can't join

  • Cannot have a brain MRI with contrast dye.
  • Cancer in the tissues or fluid around the brain and spinal cord, confirmed by a spinal tap or MRI.
  • Pregnant or breastfeeding.
  • Have had radiation treatment aimed at the brain.
  • Cancer elsewhere in the body is not controlled, has no reasonable treatment options, and is expected to cause death. This is based on CT or PET/CT scans taken within 3 months before joining.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Histologic diagnosis of small cell lung cancer * Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI * Age 18 and above * Performance status KPS 60-100/ECOG 0-2 * Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment * The patient or legally authorized representative is able to provide informed consent Exclusion Criteria: * Unable to undergo contrast-enhanced MRI brain * Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine * Pregnant or lactating women * Prior brain-directed radiotherapy * Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET/CT imaging, no more than 3 months before study enrollment

Study sites (7)

NJ

NY